Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis.

Next Previous
Trial Profile

Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efavirenz (Primary) ; Lamivudine; Stavudine; Zidovudine
  • Indications HIV infections
  • Focus Biomarker; Therapeutic Use
  • Acronyms COAT

Most Recent Events

  • 11 Mar 2020 Results (n=738), pooled analysis of the data from 3 sequential trials presented at the 27th Conference on Retroviruses and Opportunistic Infections
  • 06 Mar 2013 Primary endpoint results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
  • 06 Mar 2013 This study was halted early by the Data and Safety Monitoring Board due to a substantial excess 6-month mortality in the early ART group.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top